Abstract
Background Pre-COVID-19, individuals with TB in Nigeria were often underdiagnosed and untreated. Care for TB was mostly in the public sector while only 15% of new cases in 2019 were from the private sector. Reports highlighted challenges in accessing care in the private sector, which accounted for 67% of all initial care-seeking. Our study examined patients’ health seeking pathways for TB in Nigeria’s private sector, and explored any changes to care pathways during COVID, based on patients’ perspectives.
Design/Methods We conducted 180 cross-sectional surveys and 20 in-depth interviews with individuals having chest symptoms attending 18 high volume private clinics and hospitals in Kano and Lagos States. Questions focused on sociodemographic characteristics, health-seeking behavior and pathways to care during the COVID-19 periods. All surveys and interviews were conducted in May 2021.
Results Most participants were male (n=111, 62%), with average age of 37. Half (n=96, 53.4%) sought healthcare within a week of symptoms, while few (n=20, 11.1%) waited over 2 months. TB positive individuals had more health-seeking delays, and TB negative had more provider delays. On average, participants visited 2 providers in Kano and 1.69 in Lagos, with 61 (75%) in Kano and 48 (59%) in Lagos visiting other providers before the recruitment facility. Private providers were the initial encounters for most participants (n=60 or 66.7% in Kano, n-83 or 92.3% in Lagos). Most respondents (164 or 91%) experienced short-lived pandemic-related restrictions, particularly during the lockdowns, affecting access to transportation, and closed facilities.
Conclusions This study showed a few challenges in accessing TB healthcare in Nigeria, necessitating continued investment in healthcare infrastructure and resources, particularly in the private sector. Understanding the different care pathways and delays in care provides opportunities for targeted interventions to improve deployment of services closer to where patients first seek care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation (COVID Impact on Private Health Markets Grant INV-022420 to MP and JD). The study was implemented by the USAID-funded SHOPS Plus Project in Nigeria (Contract #: AID-OAA-A-15- 00067, https://www.usaid.gov/). EB, LR, BOF, AA and BJ were affiliated with the SHOPS Plus project and not direct recipients of a USAID contract. None of the co-authors are employees of the funding agency. The funders provided inputs on the study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study received ethical approval from the McGill University Health Centre (MUHC) Research Ethics Board (REB), with approval number Covid BMGF / 2021-7197. We also obtained approval from the health research ethics committee (HREC) in both States, including from the Lagos State University Teaching Hospital (LASUTH) and Kano State Ministry of Health (MoH). We also obtained letters of introduction from Abt Associates to the MoH, National Association of Patent and Proprietary Medicines (NAPPMED), Association of Community Pharmacists in Nigeria (ACPN), and heads of the target facilities. All survey and interview participants gave written or verbal consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was supported by the Bill and Melinda Gates Foundation (COVID Impact on Private Health Markets Grant INV-022420 to MP and JD). The study was implemented by the USAID-funded SHOPS Plus Project in Nigeria (Contract #: AID-OAA-A-15-00067, https://www.usaid.gov/). EB, LR, BOF, AA and BJ were affiliated with the SHOPS Plus project and not direct recipients of a USAID contract. None of the co-authors are employees of the funding agency. The funders provided inputs on the study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
